Veracyte, Inc. (Nasdaq: VCYT) today unveiled its inaugural Environmental, Social and Governance (ESG) Report, setting the course for the company’s ESG performance for the years to come. The 2023 ESG Report outlines Veracyte’s commitment to building on its current progress and furthering its sustainability initiatives.
Veracyte is taking the initiative to advance its ESG (Environmental, Social, and Governance) efforts with its inaugural ESG report. This report showcases how the company’s mission and values are deeply integrated into its business model, illustrating not just its dedication to improving patient outcomes, but also its commitment to its shareholders, employees, business partners, and other stakeholders. Marc Stapley, Veracyte’s Chief Executive Officer, remarked, “As our company has grown, we have embraced our responsibility to advance our ESG efforts.”
Highlights from Veracyte’s 2023 ESG Report include:
To ensure the effective integration of ESG into our corporate strategy, we have established a comprehensive governance structure, spearheaded by an executive-level ESG Steering Committee and supported by the Nominating and Corporate Governance Committee at the Board level. This framework will ensure that ESG remains a priority within the organization and that our commitment to sustainability is upheld.
At our company, we are proud to foster an inclusive and diverse workforce, as women make up 59% of our employees and 60% of our executive leadership team. We strive to create an environment that is open and welcoming to all employees and encourages different perspectives. We believe that strength lies in our diversity and we are committed to continuing to build a culture of inclusivity and respect.
At the 2023 annual meeting, Veracyte’s stockholders will have the opportunity to vote on a proposal to transition to a declassified Board of Directors – a move that would strengthen our governance practices. We encourage everyone to consider this proposal and submit their approval.
We are delighted to be working towards obtaining BREEAM® certification for our new facility in Marseille, France. BREEAM® (Building Research Establishment’s Environmental Assessment Method) is an internationally recognised standard for sustainability, and we are actively striving to meet the criteria for certification. Our commitment to sustainability is unwavering, and we are excited to be taking this important step towards a greener future.
Veracyte is a global diagnostics company with a mission to revolutionize cancer care. Our cutting-edge tests provide clinicians with the invaluable insights they need to accurately diagnose and treat cancer in patients all over the world.
From thyroid, prostate, breast, bladder and lung cancers, to interstitial lung diseases, Veracyte’s high-performing tests enable clinicians to make more informed and efficient decisions, empowering patients to avoid unnecessary procedures and get the right treatment faster.
Our tests are available in the U.S. through our central laboratories and we also strive to bring our tests to patients worldwide, via a distributed model to laboratories that can perform them locally.